Zbtb7b and Its Role in Liver Cancer Progression
Author Information
Author(s): Han Yinglin, Wu Kaimin, Peng Xin, Fu Yinkun, Li Wenyan, Ma Jing, Jiang He, Zhao Xu‐Yun
Primary Institution: Shanghai Jiao Tong University School of Medicine
Hypothesis
Zbtb7b acts as a tumor suppressor in the progression of metabolic dysfunction-associated steatotic liver disease (MASLD) related hepatocellular carcinoma (HCC).
Conclusion
Zbtb7b suppresses lipid accumulation in the liver and protects against the initiation of MASLD-related HCC.
Supporting Evidence
- Zbtb7b was found to be compensatively increased during MASLD progression.
- Zbtb7b suppresses the expression of the long noncoding RNA H19.
- Zbtb7b knockout mice showed increased lipid deposition in the liver.
- Zbtb7b overexpression inhibited the proliferation and migration of hepatic cells.
Takeaway
Zbtb7b helps keep the liver healthy by stopping too much fat from building up, which can lead to liver cancer.
Methodology
The study used a liver-specific Zbtb7b knockout mouse model to evaluate the role of Zbtb7b in MASLD-related HCC development.
Limitations
Most studies were performed at the transcriptional level, limiting the interpretation of gene function at the protein level.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website